SG11201701184WA - Novel 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative - Google Patents

Novel 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative

Info

Publication number
SG11201701184WA
SG11201701184WA SG11201701184WA SG11201701184WA SG11201701184WA SG 11201701184W A SG11201701184W A SG 11201701184WA SG 11201701184W A SG11201701184W A SG 11201701184WA SG 11201701184W A SG11201701184W A SG 11201701184WA SG 11201701184W A SG11201701184W A SG 11201701184WA
Authority
SG
Singapore
Prior art keywords
thieno
benzo
dihydro
novel
azepine derivative
Prior art date
Application number
SG11201701184WA
Other languages
English (en)
Inventor
Simon Fraser Hunt
Stuart Thomas Onions
Vladimir Sherbukhin
Euan Alexander Fraser Fordyce
Peter John Murray
Daniel William Brookes
Kazuhiro Ito
Peter Strong
Original Assignee
Pulmocide Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmocide Ltd filed Critical Pulmocide Ltd
Publication of SG11201701184WA publication Critical patent/SG11201701184WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201701184WA 2014-10-10 2015-10-08 Novel 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative SG11201701184WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14188494 2014-10-10
PCT/GB2015/052944 WO2016055791A1 (fr) 2014-10-10 2015-10-08 Nouveau dérivé d'azépine 5,6-dihydro-4 h-benzo[b]thiéno-[2,3-d]

Publications (1)

Publication Number Publication Date
SG11201701184WA true SG11201701184WA (en) 2017-03-30

Family

ID=51842340

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201701184WA SG11201701184WA (en) 2014-10-10 2015-10-08 Novel 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative

Country Status (13)

Country Link
US (6) US10189863B2 (fr)
EP (2) EP3204388B1 (fr)
JP (2) JP2017531039A (fr)
KR (1) KR20170058921A (fr)
CN (1) CN106852144B (fr)
AU (1) AU2015329789B2 (fr)
BR (1) BR112017005104B1 (fr)
CA (1) CA2957868C (fr)
EA (1) EA201790796A8 (fr)
IL (1) IL250823A0 (fr)
MX (1) MX2017004652A (fr)
SG (1) SG11201701184WA (fr)
WO (2) WO2016055791A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10189863B2 (en) * 2014-10-10 2019-01-29 Pulmocide Limited 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives
US10160772B2 (en) 2014-12-18 2018-12-25 Pulmocide Limited 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives
LT3324977T (lt) 2015-07-22 2022-10-25 Enanta Pharmaceuticals, Inc. Benzodiazepino dariniai kaip rsv inhibitoriai
US20170226129A1 (en) 2016-01-15 2017-08-10 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
EA037206B1 (ru) * 2016-02-03 2021-02-19 Янссен Сайенсиз Айрлэнд Юси Комбинация для лечения и ослабления rsv инфекции и фармацевтическая композиция на её основе
WO2017175000A1 (fr) * 2016-04-08 2017-10-12 Pulmocide Limited Composés
US10398706B2 (en) 2017-01-06 2019-09-03 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as RSV inhibitors
CA3065368A1 (fr) 2017-02-16 2018-08-23 Enanta Pharmaceuticals, Inc. Procedes pour la preparation de derives de benzodiazepine
WO2018226801A1 (fr) 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Dérivés d'aryldiazépine utilisés en tant qu'inhibiteurs du vrs
US10851115B2 (en) 2017-06-30 2020-12-01 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
WO2019006295A1 (fr) * 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. Composés hétérocycliques utilisés en tant qu'inhibiteurs du vrs
BR112020006334A2 (pt) 2017-09-29 2020-09-24 Enanta Pharmaceuticals, Inc. combinação de agentes farmacêuticos como inibidores de rsv
CA3080138A1 (fr) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Procede pour la resolution de derives benzodiazepin-2-one et benzoazepin-2-one
WO2019094920A1 (fr) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Dérivés d'azépin-2-one en tant qu'inhibiteurs du vrs
WO2019199908A1 (fr) * 2018-04-11 2019-10-17 Enanta Pharmaceuticals, Inc. Composés hétérocycliques en tant qu'inhibiteurs de vrs
UY38614A (es) 2019-03-18 2020-10-30 Enanta Pharm Inc Derivados de benzodiazepinas como inhibidores del rsv
US11179400B2 (en) 2019-04-09 2021-11-23 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
CA3153297A1 (fr) 2019-10-04 2021-04-08 Adam SZYMANIAK Composes heterocycliques antiviraux
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
WO2022010882A1 (fr) * 2020-07-07 2022-01-13 Enanta Pharmaceuticals, Inc, Dérivés de dihydroquinoxaline et de dihydropyridopyrazine utilisés comme inhibiteurs de rsv
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
MX2023009961A (es) 2021-02-26 2023-09-05 Enanta Pharm Inc Compuestos heterociclicos antivirales.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693635A (en) 1993-07-29 1997-12-02 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
KR100693771B1 (ko) 1999-04-28 2007-03-12 사노피-아벤티스 도이칠란트 게엠베하 Ｐｐａｒ 수용체 리간드로서의 트리아릴 산 유도체 및 이를 포함하는 약제학적 조성물
AU2009204147A1 (en) * 2008-01-07 2009-07-16 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2011005842A1 (fr) * 2009-07-09 2011-01-13 Gilead Sciences, Inc. Composés anti-vrs
CN102656141B (zh) 2009-10-13 2016-04-06 利亘制药公司 模拟造血生长因子的小分子化合物及其用途
KR101764952B1 (ko) 2010-07-29 2017-08-03 리겔 파마슈티칼스, 인크. Ａｍｐｋ-활성화 헤테로시클릭 화합물 및 그의 사용 방법
WO2012129562A2 (fr) 2011-03-24 2012-09-27 The Scripps Research Institute Composés et procédés pour l'induction de la chondrogenèse
WO2016022464A1 (fr) 2014-08-05 2016-02-11 Alios Biopharma, Inc. Polythérapie pour traiter un paramyxovirus
US10189863B2 (en) * 2014-10-10 2019-01-29 Pulmocide Limited 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives
US20170226129A1 (en) 2016-01-15 2017-08-10 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
EA037206B1 (ru) 2016-02-03 2021-02-19 Янссен Сайенсиз Айрлэнд Юси Комбинация для лечения и ослабления rsv инфекции и фармацевтическая композиция на её основе
US10851115B2 (en) 2017-06-30 2020-12-01 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
WO2019006295A1 (fr) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. Composés hétérocycliques utilisés en tant qu'inhibiteurs du vrs

Also Published As

Publication number Publication date
EP3204388B1 (fr) 2018-12-12
JP2017531039A (ja) 2017-10-19
EP3204389A1 (fr) 2017-08-16
US10189863B2 (en) 2019-01-29
AU2015329789B2 (en) 2019-09-26
EP3204388A1 (fr) 2017-08-16
CN106852144B (zh) 2019-08-30
KR20170058921A (ko) 2017-05-29
US20170190718A1 (en) 2017-07-06
IL250823A0 (en) 2017-04-30
US10273249B2 (en) 2019-04-30
JP6675407B2 (ja) 2020-04-01
US20190202841A1 (en) 2019-07-04
US20180319820A1 (en) 2018-11-08
BR112017005104A2 (pt) 2017-12-05
EA201790796A1 (ru) 2017-09-29
CA2957868C (fr) 2023-02-28
BR112017005104B1 (pt) 2022-08-23
EP3204389B1 (fr) 2019-06-26
JP2017531038A (ja) 2017-10-19
EA201790796A8 (ru) 2018-10-31
AU2015329789A1 (en) 2017-03-09
US20180179228A1 (en) 2018-06-28
US10035810B2 (en) 2018-07-31
WO2016055791A1 (fr) 2016-04-14
WO2016055792A1 (fr) 2016-04-14
CN106852144A (zh) 2017-06-13
US20170355717A1 (en) 2017-12-14
MX2017004652A (es) 2017-06-19
US10472375B2 (en) 2019-11-12
US20170305935A1 (en) 2017-10-26
US9732098B2 (en) 2017-08-15
US9926335B2 (en) 2018-03-27
CA2957868A1 (fr) 2016-04-14

Similar Documents

Publication Publication Date Title
IL250823A0 (en) A new derivative of 6,5-dihydro-h4-benzo[b]thiano-[3,2-d]azepine
HK1244804A1 (zh) 4h-吡咯並[3，2-c]吡啶-4-酮衍生物
IL252053A0 (en) Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
GB201516092D0 (en) Electrical bicycle modular powertrain
IL254167A0 (en) Combinations containing modified 3,2-dihydroimidazo[2,1-c]quinazoline
HUE051002T2 (hu) Citotoxikus benzodiazepin származékok
EP3452481A4 (fr) Imidazo[1,2-b]pyridazines substituées, imidazo[1,5-b]pyridazines substituées, composés apparentés et leur utilisation dans le traitement de troubles médicaux
IL257413A (en) Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials
IL260298B (en) 6,7,8,9-tetrahydro-5h-pyrido[2,3-d]azepine dopamine d3 ligands
IL271665A (en) benzazapine derivatives
GB201414116D0 (en) Benzodiazepine derivatives
SG11201803584RA (en) 1,4-dicarbonyl-piperidyl derivatives
HK1254800A1 (zh) 2，3，4，5-四氫吡啶-6-胺衍生物
GB201522532D0 (en) Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
EP3149084A4 (fr) Polyamides à faible couleur et faible teneur en phosphore
ZA201700823B (en) A tetrahydropyrrolo[3,4-d][1,3]thiazine-derivative as bace inhibitor
ZA201606522B (en) Novel 6,7-dihydro-3h-oxazolo[3,4-a]pyrazine-5,8-dione derivative compounds
ZA201801639B (en) Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials
ZA202000438B (en) Benzazepine derivatives
GB201300892D0 (en) Novel isothiazolo[4,3-b]pyridines